Unknown

Dataset Information

0

HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.


ABSTRACT: Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). Therefore, we have developed an affibody-based PET radioconjugate that quantitatively assesses HER3 changes induced by Hsp90 inhibition in vivoExperimental Design: ZHER3:8698 affibody molecules were conjugated via the C-terminus cysteine to DFO-maleimide for 89Zr radiolabeling. The probe was characterized in vitro and in vivo in a panel of human breast cell lines and xenograft models with varying HER3 receptor levels. In addition, the radioconjugate was investigated as a tool to monitor the outcome of AUY922, an Hsp90 inhibitor, in an MCF-7 xenograft model.Results: We demonstrated that 89Zr-DFO-ZHER3:8698 can track changes in receptor expression in HER3-positive xenograft models and monitor the outcome of AUY922 treatment. Our in vitro findings showed that MCF-7 cells, which are phenotypically different from BT474, develop resistance to treatment with AUY922 through HER3/IGF-1R?-mediated signaling. Of note, the lack of response in vitro due to HER3 recovery was confirmed in vivo using 89Zr-DFO-ZHER3:8698-based imaging. Upon AUY922 treatment, higher radioconjugate uptake was detected in treated MCF-7 xenografts, correlating with an AUY922-induced HER3 upregulation concomitant with an increase in IGF-1R? expression.Conclusions: These data underline the potential of HER3-based PET imaging to noninvasively provide information about HER3 expression and to identify patients not responding to targeted therapies due to HER3 recovery. Clin Cancer Res; 24(8); 1853-65. ©2018 AACR.

SUBMITTER: Martins CD 

PROVIDER: S-EPMC6296444 | biostudies-other | 2018 Apr

REPOSITORIES: biostudies-other

altmetric image

Publications

HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.

Martins Carlos D CD   Da Pieve Chiara C   Burley Thomas A TA   Smith Rhodri R   Ciobota Daniela M DM   Allott Louis L   Harrington Kevin J KJ   Oyen Wim J G WJG   Smith Graham G   Kramer-Marek Gabriela G  

Clinical cancer research : an official journal of the American Association for Cancer Research 20180206 8


<b>Purpose:</b> Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). Therefore, we have developed an affibody-based PET radioconjugate that quantitatively assesses HER3 changes induced by Hsp90 inhibition <i>in vivo</i><b>Experimental Design:</b> Z<sub>HER3:8698</sub> affibody molecules were conjugated via the C-terminus cysteine to DFO  ...[more]

Similar Datasets

| S-EPMC4609989 | biostudies-other
| S-EPMC8508546 | biostudies-literature
| S-EPMC7139902 | biostudies-literature
| S-EPMC5433087 | biostudies-literature
| S-EPMC7139392 | biostudies-literature
| S-EPMC3386944 | biostudies-literature
| S-EPMC6494909 | biostudies-other
| S-EPMC6345776 | biostudies-literature
| S-EPMC6160764 | biostudies-literature
| S-EPMC7271293 | biostudies-literature